GSK halts development of anti-emetic casopitant
This article was originally published in Scrip
Executive Summary
Safety issues have scuttled GlaxoSmithKline's worldwide development and commercialisation plans for the investigational anti-emetic Rezonic/Zunrisa (casopitant).